Lucid Diagnostics (LUCD) Profit After Tax Growth (1y) (2021 - 2026)
Lucid Diagnostics (LUCD) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 18.66% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 13.84% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -27.98% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 14.60% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 71.04% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.92% |
| 10 | Lucid Diagnostics | 175.80 Mn | 142.40 Mn | 55,000.00 | -163.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -163.28% |
| Mar 31, 2026 | 48.31% |
| Dec 31, 2025 | -40.94% |
| Sep 30, 2025 | 15.96% |
| Jun 30, 2025 | 59.66% |
| Mar 31, 2025 | -153.56% |
| Dec 31, 2024 | -6.57% |
| Sep 30, 2024 | 12.93% |
| Jun 30, 2024 | 3.30% |
| Mar 31, 2024 | 34.68% |
| Dec 31, 2023 | 27.45% |
| Sep 30, 2023 | 0.98% |
| Jun 30, 2023 | 22.18% |
| Mar 31, 2023 | -32.41% |
| Dec 31, 2022 | -32.04% |
| Sep 30, 2022 | -106.25% |
| Jun 30, 2022 | -137.29% |
| Mar 31, 2022 | -235.89% |
| Dec 31, 2021 | -313.97% |
| Sep 30, 2021 | -244.12% |